Chesapeake Asset Management’s Definium Therapeutics DFTX Stock Holding History

Chesapeake Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$623	Hold	33	–	–	﹤0.01%	317
2025 Q4	$441	Hold	33	–	–	﹤0.01%	343
2025 Q3	$389	Hold	33	–	–	﹤0.01%	305
2025 Q2	$214	Hold	33	–	–	﹤0.01%	312
2025 Q1	$193	Hold	33	–	–	﹤0.01%	520
2024 Q4	$229	Hold	33	–	–	﹤0.01%	479
2024 Q3	$187	Hold	33	–	–	﹤0.01%	493
2024 Q2	$237	Hold	33	–	–	﹤0.01%	323
2024 Q1	$310	Hold	33	–	–	﹤0.01%	305
2023 Q4	$120	Hold	33	–	–	﹤0.01%	371
2023 Q3	$103	Hold	33	–	–	﹤0.01%	421
2023 Q2	$117	Hold	33	–	–	﹤0.01%	409
2023 Q1	$104	Buy	+33	New	+$110	﹤0.01%	405

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chesapeake Asset Management's DFTX Position: Q1 2026 in Review

Chesapeake Asset Management held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 33 shares worth $623. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Chesapeake Asset Management first reported a position in DFTX in Q1 2023 and has held it in 13 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Chesapeake Asset Management held 33 shares of Definium Therapeutics worth $623 as of Q1 2026.
Chesapeake Asset Management left its Definium Therapeutics share count unchanged in Q1 2026.
Definium Therapeutics made up ﹤0.01% of Chesapeake Asset Management's portfolio in Q1 2026, its #317 holding.
Chesapeake Asset Management first reported a position in Definium Therapeutics in Q1 2023 and has held it in 13 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Chesapeake Asset Management's 13F filing for Q1 2026, filed 12 May 2026.